Modulation of interactions between myosin and integrins
CA 2271935 A1 · Owner: Millennium Pharmaceuticals, Inc. · Inventors: Phillips, David R.; Jenkins, Alison L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention describes a direct interaction between myosin and the cytoplasmic domain of membrane proteins particularly the phosphorylated , cytoplasmic domains of the .beta.-subunit of integrins. The invention provides methods of identifying agents which block integrin binding to myosin methods , of using agents which block integrin binding to myosin to modulate biological and pathological processes, and provides agents that block integrin mediated binding to myosin and thereby modulate related cellular or cellular component movement.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 21, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 21, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 21, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.